PHAR (Pharming Group) Cyclically Adjusted Revenue per Share: $3.60 (As of Mar. 2026)


PHAR Pharming Group PHAR
77 GF Score
Price $13.72
GF Value $14.73
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Cyclically Adjusted Revenue per Share?

Pharming Group PHAR -2.26% 77 Cyclically Adjusted Revenue per Share is $3.60 as of Mar. 2026. GuruFocus rates PHAR with a GF Score™ of 77/100 and a GF Value™ of $14.73 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharming Group's adjusted revenue per share for the three months ended in Mar. 2026 was $0.973. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.60 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pharming Group's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharming Group was 23.30% per year. The lowest was 17.30% per year. And the median was 18.60% per year.

As of today (2026-07-12), Pharming Group's current stock price is $13.72. Pharming Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $3.60. Pharming Group's Cyclically Adjusted PS Ratio of today is 3.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharming Group was 22.01. The lowest was 2.65. And the median was 6.16.


Pharming Group  (NAS:PHAR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharming Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.72/3.60
=3.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharming Group was 22.01. The lowest was 2.65. And the median was 6.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharming Group Cyclically Adjusted Revenue per Share Related Terms


Pharming Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharming Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Cyclically Adjusted Revenue per Share Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.73 1.83 2.33 2.72 3.72

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.80 3.17 3.38 3.72 3.60

PHAR vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted PS Ratio falls into.


PHAR
77GF Score
Pharming Group PHAR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharming Group's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.973/136.9100*136.9100
=0.973

Current CPI (Mar. 2026) = 136.9100.

Pharming Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.080 100.260 0.109
201609 0.093 100.570 0.127
201612 0.152 100.710 0.207
201703 0.345 101.440 0.466
201706 0.383 101.370 0.517
201709 0.610 102.030 0.819
201712 0.707 101.970 0.949
201803 0.530 102.470 0.708
201806 0.508 103.100 0.675
201809 0.667 103.950 0.878
201812 0.640 103.970 0.843
201903 0.587 105.370 0.763
201906 0.745 105.840 0.964
201909 0.689 106.700 0.884
201912 0.789 106.800 1.011
202003 0.710 106.850 0.910
202006 0.661 107.510 0.842
202009 0.788 107.880 1.000
202012 0.864 107.850 1.097
202103 0.664 108.870 0.835
202106 0.572 109.670 0.714
202109 0.663 110.790 0.819
202112 0.790 114.010 0.949
202203 0.673 119.460 0.771
202206 0.674 119.050 0.775
202209 0.790 126.890 0.852
202212 0.774 124.940 0.848
202303 0.662 124.720 0.727
202306 0.681 125.830 0.741
202309 0.962 127.160 1.036
202312 0.926 126.450 1.003
202403 0.848 128.580 0.903
202406 0.809 129.910 0.853
202409 1.448 131.610 1.506
202412 1.279 131.630 1.330
202503 1.182 133.330 1.214
202506 1.138 133.960 1.163
202509 1.396 135.920 1.406
202512 1.407 135.270 1.424
202603 0.973 136.910 0.973

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $3.60 mean?
Pharming Group (PHAR) has a Cyclically Adjusted Revenue per Share of $3.60 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharming Group and its competitors.
Is Pharming Group's Cyclically Adjusted Revenue per Share too high?
Pharming Group's current Cyclically Adjusted Revenue per Share is $3.60. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Pharming Group's Cyclically Adjusted Revenue per Share of $3.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharming Group and its competitors. Pharming Group's current Cyclically Adjusted Revenue per Share is $3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.73, compared to a current price of $13.72 — trading 6.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $3.60. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharming Group (PHAR), the current Cyclically Adjusted Revenue per Share is $3.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.72 is trading 6.9% below its estimated GF Value™ of $14.73. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Cyclically Adjusted Revenue per Share: $3.60
  • GF Value™: $14.73 vs. price of $13.72 (6.9% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score

Get the complete analysis for PHAR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.72
Price
$14.73
GF Value